Cargando…

Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model

BACKGROUND: Antigen tests for SARS-CoV-2 offer advantages over nucleic acid amplification tests (NAATs, such as RT-PCR), including lower cost and rapid return of results, but show reduced sensitivity. Public health organizations recommend different strategies for utilizing NAATs and antigen tests. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvatore, Phillip P., Shah, Melisa M., Ford, Laura, Delaney, Augustina, Hsu, Christopher H., Tate, Jacqueline E., Kirking, Hannah L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756411/
https://www.ncbi.nlm.nih.gov/pubmed/35027019
http://dx.doi.org/10.1186/s12889-021-12489-8
_version_ 1784632561726652416
author Salvatore, Phillip P.
Shah, Melisa M.
Ford, Laura
Delaney, Augustina
Hsu, Christopher H.
Tate, Jacqueline E.
Kirking, Hannah L.
author_facet Salvatore, Phillip P.
Shah, Melisa M.
Ford, Laura
Delaney, Augustina
Hsu, Christopher H.
Tate, Jacqueline E.
Kirking, Hannah L.
author_sort Salvatore, Phillip P.
collection PubMed
description BACKGROUND: Antigen tests for SARS-CoV-2 offer advantages over nucleic acid amplification tests (NAATs, such as RT-PCR), including lower cost and rapid return of results, but show reduced sensitivity. Public health organizations recommend different strategies for utilizing NAATs and antigen tests. We sought to create a framework for the quantitative comparison of these recommended strategies based on their expected performance. METHODS: We utilized a decision analysis approach to simulate the expected outcomes of six testing algorithms analogous to strategies recommended by public health organizations. Each algorithm was simulated 50,000 times in a population of 100,000 persons seeking testing. Primary outcomes were number of missed cases, number of false-positive diagnoses, and total test volumes. Outcome medians and 95% uncertainty ranges (URs) were reported. RESULTS: Algorithms that use NAATs to confirm all negative antigen results minimized missed cases but required high NAAT capacity: 92,200 (95% UR: 91,200-93,200) tests (in addition to 100,000 antigen tests) at 10% prevalence. Selective use of NAATs to confirm antigen results when discordant with symptom status (e.g., symptomatic persons with negative antigen results) resulted in the most efficient use of NAATs, with 25 NAATs (95% UR: 13-57) needed to detect one additional case compared to exclusive use of antigen tests. CONCLUSIONS: No single SARS-CoV-2 testing algorithm is likely to be optimal across settings with different levels of prevalence and for all programmatic priorities. This analysis provides a framework for selecting setting-specific strategies to achieve acceptable balances and trade-offs between programmatic priorities and resource constraints. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-12489-8.
format Online
Article
Text
id pubmed-8756411
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87564112022-01-13 Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model Salvatore, Phillip P. Shah, Melisa M. Ford, Laura Delaney, Augustina Hsu, Christopher H. Tate, Jacqueline E. Kirking, Hannah L. BMC Public Health Research BACKGROUND: Antigen tests for SARS-CoV-2 offer advantages over nucleic acid amplification tests (NAATs, such as RT-PCR), including lower cost and rapid return of results, but show reduced sensitivity. Public health organizations recommend different strategies for utilizing NAATs and antigen tests. We sought to create a framework for the quantitative comparison of these recommended strategies based on their expected performance. METHODS: We utilized a decision analysis approach to simulate the expected outcomes of six testing algorithms analogous to strategies recommended by public health organizations. Each algorithm was simulated 50,000 times in a population of 100,000 persons seeking testing. Primary outcomes were number of missed cases, number of false-positive diagnoses, and total test volumes. Outcome medians and 95% uncertainty ranges (URs) were reported. RESULTS: Algorithms that use NAATs to confirm all negative antigen results minimized missed cases but required high NAAT capacity: 92,200 (95% UR: 91,200-93,200) tests (in addition to 100,000 antigen tests) at 10% prevalence. Selective use of NAATs to confirm antigen results when discordant with symptom status (e.g., symptomatic persons with negative antigen results) resulted in the most efficient use of NAATs, with 25 NAATs (95% UR: 13-57) needed to detect one additional case compared to exclusive use of antigen tests. CONCLUSIONS: No single SARS-CoV-2 testing algorithm is likely to be optimal across settings with different levels of prevalence and for all programmatic priorities. This analysis provides a framework for selecting setting-specific strategies to achieve acceptable balances and trade-offs between programmatic priorities and resource constraints. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-021-12489-8. BioMed Central 2022-01-13 /pmc/articles/PMC8756411/ /pubmed/35027019 http://dx.doi.org/10.1186/s12889-021-12489-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Salvatore, Phillip P.
Shah, Melisa M.
Ford, Laura
Delaney, Augustina
Hsu, Christopher H.
Tate, Jacqueline E.
Kirking, Hannah L.
Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
title Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
title_full Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
title_fullStr Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
title_full_unstemmed Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
title_short Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
title_sort quantitative comparison of sars-cov-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756411/
https://www.ncbi.nlm.nih.gov/pubmed/35027019
http://dx.doi.org/10.1186/s12889-021-12489-8
work_keys_str_mv AT salvatorephillipp quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel
AT shahmelisam quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel
AT fordlaura quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel
AT delaneyaugustina quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel
AT hsuchristopherh quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel
AT tatejacquelinee quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel
AT kirkinghannahl quantitativecomparisonofsarscov2nucleicacidamplificationtestandantigentestingalgorithmsadecisionanalysissimulationmodel